Drug Trial Radar · NCT03896685
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
323
Actual
Start
Apr 6, 2020
Primary completion
Oct 4, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Médecins Sans Frontières, FranceAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Partners in Health; Harvard Medical School (HMS and HSDM); Epicentre; Institute of Tropical Medicine, Belgium; Socios En Salud, Peru; Interactive Research and Development; University of San Francisco
- First posted
- Apr 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
endTB-Q Clinical Trial is a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of two new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB) with fluoroquinolone resistance.
Conditions
- Tuberculosis, Multidrug-Resistant
- Tuberculosis
- Pulmonary Tuberculoses
- Mycobacterial Infections
- Bacterial Infections
- Gram-Positive Bacterial Infections
Interventions
Bedaquiline 100 MGDrug
Bedaquiline: 400 mg QD x 2 weeks, followed by 200 mg 3x/week
Delamanid 50 MG Oral TabletDrug
Delamanid: 100 mg BID
Clofazimine 100 MG Oral CapsuleDrug
Clofazimine: 100 mg QD
Linezolid 600Mg TabDrug
Linezolid: 600 mg QD up to Week 16, followed by 300 mg QD or 600 mg 3x/week according to a secondary randomization
Control arm MDR-TB regimen, designed according to latest WHO guidelinesDrug
Control arm MDR-TB regimen, designed according to latest WHO guidelines (might include bedaquiline, delamanid, linezolid, clofazimine, or all of these drugs).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Week 73 Efficacy: Proportion of participants with favorable outcome at Week 73Time frame: Week 73 after randomization
Locations
10 sites in 6 countries. Site status is shown where the registry gives one.
Aundh Chest Hospital
Pune, India
National Center for Tuberculosis Problems
Almaty, Kazakhstan
State Municipal Enterprise on the right of economic management "City Centre of Phthisiopulmonology" of Nur-sultan city's administration
Almaty, Kazakhstan
Partners In Health Lesostho
Maseru, Lesotho
The Indus Hospital
Karachi, Pakistan
Institute of Chest Disease,
Kotri, Pakistan
Centro de Investigación del Hospital Nacional Hipólito Unanue
Lima, Peru
Centro de Investigación de Enfermedades Neumológicas del Hospital Nacional Sergio Bernales
Lima, Peru
Hanoi Lung Hospital
Hanoi, Vietnam
Pham Ngoc Thach Hospital
Ho Chi Minh City, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.